Streetbeat News

OKYO

OKYO Pharma Limited

https://www.okyopharma.com

Industry

Biotechnology

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Open

1.10

Mkt cap

38M

Volume

32K

High

1.17

P/E Ratio

-1.98

52-wk high

2.12

Low

1.07

Div yield

N/A

52-wk low

0.81

In Friday's after-market session, several healthcare stocks experienced significant price movements. Healthcare Triangle, Mira Pharmaceuticals, MEI Pharma, TuHURA Biosciences, P3 Health Partners, and OKYO Pharma saw notable gains, while Aclaris Therapeutics, Beyond Air, Qualigen Therapeutics, Nuwellis, Compass Pathways, and Helius Medical Tech experienced declines.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 8:31 pm

Viking Therapeutics saw a significant stock price increase of 22.8% following its Q3 earnings report, while Intellia Therapeutics and OKYO Pharma experienced declines of 18.3% and 10.56%, respectively, during Thursday's session.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 4:37 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on OKYO Pharma and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:02 am

OKYO Pharma's shares rose following the announcement of dosing the first patient in a clinical trial for Neuropathic Corneal pain treatment.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 5:47 pm

OKYO Pharma has dosed the first patient in its clinical trial aimed at treating neuropathic corneal pain. This marks a significant milestone in the development of their treatment, potentially impacting the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 11:08 am

HC Wainwright & Co. has reiterated its Buy rating for OKYO Pharma, maintaining a price target of $7. Analyst Yi Chen continues to support the stock, indicating confidence in its potential growth.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 6:39 pm

OKYO Pharma has commenced patient screening and recruitment for a Phase 2 trial of OK-101 for neuropathic corneal pain. The trial will involve 48 patients and aims to measure pain relief using the Visual Analog Scale.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:05 am

OKYO Pharma's Executive Chairman, Gabriele Cerrone, has increased his stake in the company by purchasing an additional 50,000 shares on NASDAQ at $1.03 each. This acquisition raises his total ownership to 29.12% of the company's issued share capital.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:05 am

OKYO Pharma's shares rose following the announcement of a US Patent for OK-101, a treatment for dry eye disease.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 7:20 pm

HC Wainwright & Co. has reiterated its Buy rating on OKYO Pharma, maintaining a price target of $7. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 4:38 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.